



Press release 2014-12-16

Order for three C-RAD systems from German customer

C-RAD secured an order of two Catalyst HD™ systems as well as a Sentinel™ system from Klinikum Chemnitz, which operates the radiation oncology clinic in Chemnitz, Germany. An option for a long-term service contract has also been negotiated. The total order value including options is worth 3.5 MSEK.

The Catalyst HDs will be delivered with the complete software configuration containing modules for Respiratory Gating, Patient Setup and Positioning, and Motion Monitoring as well as interfaces to the existing CT and linear accelerators. The customer also decided on the unique audio-visual couching functionality that supports an interactive gating mode.

The delivery and installation of the first two systems will be in the summer of 2015, while the third system will be delivered in the following year.

The Catalyst™ and Sentinel™ systems offer the required technology to perform high-end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery. Respiratory gated treatments are frequently used when the target volume is close to cardiac tissue or for special treatments in which the tumor position depends on the respiratory cycle.

“I am glad to be able to welcome the team from Klinikum Chemnitz very soon into our family of C-RAD users,” says Tim Thurn, CEO of C-RAD. “The Catalyst HD system was specifically developed for use in stereotactic treatment. Its functionality gives our customers the opportunity to monitor the patient prior and during treatment to increase accuracy and safety. I am also very pleased with our sales development in our major regions. Among the western countries – especially the US, but also central Europe – there is still a high potential for C-RAD products.”

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 28. C-RAD's business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD holds 29% of the laser company Cyrpa with an option to acquire the remaining 71%. C-RAD AB is listed – since March 2010 – on NASDAQ OMX First North Premier. Erik Penser Bankaktiefbolag is appointed as C-RAD's Certified Adviser.

For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, Email investors@c-rad.com



The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2077:528).